AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00914823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kisspeptin 112-121
Description: One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121
Study NCT00914823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: One or more IV doses of GnRH, and/or SC administration of GnRH
Study NCT03018119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Study NCT03680391 — intervention group
Intervention type: PROCEDURE
Intervention: Cesarean section
Description: Both groups cesarean section will be held with the same technique:~* spinal anethesia~* pfennenstiel imcision~* lower segment cesarean section~* suturing uterus in two layers while exterionezed~* gentle manibulation~* no towels in gutters will be used
Study NCT04166682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Description: cardiac rehabilitation done at home
Study NCT04166682 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine care
Description: Routine care and followup
Study NCT04365855 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver biopsy
Description: If indicated per MRE results a biopsy will be taken of the liver.
Study NCT02462304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-Point-Management grid laser
Study NCT02462304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Study NCT02462304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT02462304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT02462304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01168713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5
Study NCT01168713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEM-101
Description: CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5
Study NCT01119274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm
Description: Loading and monitoring dose according to genotype-guided dosing algorithm
Study NCT01119274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-genotype-guided dosing algorithm
Description: Loading and monitoring dose according to non-genotype-guided dosing algorithm
Study NCT01428063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT01428063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Study NCT04365855 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fibro Scan
Description: If indicated per MRE results a fibroscan will be performed of the liver.
Study NCT01661283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 10 mg tablet once daily
Study NCT02968004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: Once weekly subcutaneous injection using pre-filled pen device.
Study NCT02968004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Once daily subcutaneous injection of Genotropin using pre-filled pen device.
Study NCT02337010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CeVOX
Description: Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
Study NCT02337010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CVP
Description: Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
Study NCT02337010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid bolus
Description: If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
Study NCT02337010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid bolus
Description: If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
Study NCT02337010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressor
Description: If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
Study NCT02337010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressor
Description: If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
Study NCT01428063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Study NCT01428063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT02142179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge about Asthma and Respiratory Education (KARE)
Description: KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
Study NCT00920608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056
Description: Tablets for oral use. 400 mg once daily for 7 days
Study NCT00920608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
Study NCT04077970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrauterine flushing of follicular fluid with granulosa cells
Description: All patients in case and control groups will receive agonist and antagonist protocol. Ovarian stimulation will be carried out when pituitary desensitization is achieved and is continued until the day of hCG administration. COCs aspiration will be performed 34-36h after hCG injection. Clear Follicular Fluids (without blood cells) which contain COCs will be used. Endometrial flushing after oocyte retrieval with 2 ml of clear FF plus granulose cells will be performed by an IUI catheter. The control group included 70 women who would not have FF endometrial flushing. In both groups, embryo transfer will be carried out 2-3 days later. Luteal phase support will be started the day after ovum pick up by the vaginal administration of progesterone daily for 16 days and will continued for up to12 weeks if pregnancy occurred. Pregnancy was diagnosed by measurement of β-hCG level and later was confirmed by Transvaginal sonography.
Study NCT02330627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Valence System Treatment
Description: Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
Study NCT03502252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semillas de Apego
Description: Group-based Primary Caregiver Intervention: Group-based psychosocial program for victimized mothers (or alternative primary caregivers) with children 2 to 5, that aims at promoting healthy child-parent attachments as a pathway for a proper development among children exposed to violence.
Study NCT03899129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simultaneous working length control using E-CONNECT S
Description: E-CONNECT S (Eighteeth medical technology Co., Ltd, china) is an endomotor with integrated apex locator newly introduced in the market with continuous WL measuring function. It contains an optional module for rotary instrumentation, allowing the device to function as a low-speed handpiece, apex locator, or a combination of both. This motor has an attention-grabbing property that when an instrument reaches the predetermined working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).
Study NCT03899129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: separate length determination and root canal preparation using Root ZX apex locator.
Description: Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
Study NCT03161639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomies
Description: Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
Study NCT03657914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-hole inflatable mediastinal mirror
Description: The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
Study NCT03397615 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Betadine douches
Description: subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
Study NCT01661283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg dose every 14 days
Study NCT00784615 — intervention group
Intervention type: PROCEDURE
Intervention: Blood samples, transvaginal ultrasound
Description: Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
Study NCT03779425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Physical Therapy
Description: Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
Study NCT04539249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Description: 1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section.
Study NCT04539249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentazocine
Description: Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is > 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section.
Study NCT04261634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor Membrane
Description: Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study NCT04261634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated Growth Factor Membrane
Description: Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study NCT04261634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study NCT04261634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Fibrin
Description: Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study NCT01313312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U.
Study NCT03993132 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: new users (initiators) of Empagliflozin
Study NCT03993132 — intervention group
Intervention type: DRUG
Intervention: Liraglutide
Description: initiators of Liraglutide
Study NCT01034189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3\~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
Study NCT01260467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: 10 milligrams orally twice a day
Study NCT01034189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
Study NCT01034189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
Study NCT02488551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-delivered CALM
Description: This intervention includes the delivery of CALM via computer
Study NCT02488551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual-delivered CALM
Description: This active comparison condition includes the delivery of CALM via manual
Study NCT00524316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Transarterial chemoembolization
Study NCT00524316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given Orally
Study NCT00524316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Study
Study NCT00524316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery embolization
Description: Surgical procedure
Study NCT00524316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Correlative Study
Study NCT00251407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
Study NCT01034189 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
Study NCT03414320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gathering data
Description: Gathering data about sleep, heart rate, carbohydrate intake, insulin pump, continuous glucose sensor, meals.
Study NCT00671333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LRTI
Description: Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
Study NCT00671333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ascension PyroDisk
Description: Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
Study NCT01769989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrodermabrasion
Study NCT01769989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Study NCT04203797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Pre-filled syringe administered by subcutaneous (SC) injections
Study NCT04203797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Pre-filled syringe administered by subcutaneous (SC)
Study NCT02433457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292
Study NCT02433457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Omeprazole (OMP)
Study NCT00023946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT00023946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02326051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
Study NCT02326051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
Study NCT01768143 — intervention group
Intervention type: BEHAVIORAL
Intervention: unexperienced endoscopy nurses
Study NCT01768143 — intervention group
Intervention type: BEHAVIORAL
Intervention: Experienced endoscopy nurses
Study NCT05280964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Together Physician Coaching
Description: 6 month, online group coaching program
Study NCT00087269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00087269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic endoscopic surgery
Description: Undergo surgical resection
Study NCT00087269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04311229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative-Pressure Wound Therapy group
Description: The wounds were initially evaluated for any necrotic findings and debrided if needed, and then washed with an antiseptic solution. 3-DWM was used to measure the pressure sores by taking pictures.The length and width of wounds were measured with disposable paper rulers. Wound depth was determined in centimeters with a sterile cotton-tip applicator by measuring against a ruler. The wound was closed using a Wound Care Kit that includes foam dressing, film drape, TRAC pad with tubing and a drainage canister. Foam material was placed inside the wound and was attached to the canister through tubing.The canister was attached to the Vacuum-Assisted Closure device, which is a portable device that applies intermittent or continuous negative pressure.The device was operated at 125 mmHg pressure for 5 minutes with and 2 minutes without active vacuum.Wound dressings were changed every 48 hours.Wound area was measured after all three rounds of treatment.